Moderna Reports Strong Q3 2025 Performance with mNEXSPIKE Capturing 24% of US COVID Vaccine Market
核心洞察
Moderna's new COVID vaccine mNEXSPIKE (搜索) achieved remarkable market penetration, capturing 24% of US retail COVID vaccinations in 2025 despite its midyear launch and representing 55% of the company's COVID vaccination volume.
The company demonstrated exceptional financial discipline by reducing cash costs by $2.1 billion over four quarters and beating 2025 cost projections by $900 million, with year-end cash guidance increased to $6.5-7 billion.
Moderna's diversified pipeline advanced significantly with three approved commercial products, multiple Phase III programs in oncology including fully enrolled adjuvant melanoma (搜索) trials, and expanded global manufacturing capabilities across the UK, Canada, and Australia.
Moderna delivered strong third-quarter 2025 results, showcasing the successful launch of its next-generation COVID vaccine mNEXSPIKE (搜索) while maintaining strict financial discipline amid a transitioning market landscape. The company reported total revenue of $1 billion for Q3 2025, with its new COVID vaccine capturing significant market share despite launching midyear.
mNEXSPIKE Drives Market Share Gains
The standout performance came from mNEXSPIKE (搜索), Moderna's enhanced COVID vaccine that now represents 55% of the company's COVID vaccination volume and has captured 24% of the US retail COVID vaccination market. Stephen Hoge, President, noted that "mNEXSPIKE now makes up 55% of our COVID vaccination volume" and emphasized the strong market uptake despite the midyear launch.
Moderna's overall COVID retail market share reached 42%, up 2 percentage points from the previous year. The company's US revenue guidance for 2025 remains at $1.0-1.3 billion, based on vaccination rates declining 20-40% from fall 2024 levels. As of October 24, 2025, cumulative retail vaccinations were 13.2 million, down approximately 30% year-over-year but within the company's projected range.
Exceptional Cost Management Delivers Results
Chief Financial Officer James Mock highlighted the company's remarkable cost reduction achievements, stating: "Over the last 4 quarters, Q4 2024 to Q3 2025, we delivered a $2.1 billion improvement in costs across cost of goods, SG&A and R&D versus the prior 4 quarters."
The company exceeded its cost reduction targets by $900 million on a cash basis, reducing projected 2025 cash costs from $5.5 billion to $4.6 billion. This represents a 50% reduction from the nearly $9 billion in cash costs recorded in 2023. As a result, Moderna increased its year-end cash guidance to $6.5-7 billion, up from the previous guidance of approximately $6 billion.
R&D expenses decreased 30% year-over-year to $801 million in Q3, primarily reflecting lower clinical trial costs as several large Phase III vaccine studies completed. Cost of sales improved dramatically, falling 60% year-over-year to $207 million, representing 21% of net product sales.
Diversified Pipeline Shows Strong Progress
Moderna's pipeline now consists of three approved products, two programs with positive Phase III results, and five additional candidates in clinical studies with registrational potential. The company made significant advances across multiple therapeutic areas.
In oncology, the intismeran (搜索) program, partnered with Merck (搜索), continues to progress with several late-stage studies. The Phase III adjuvant melanoma (搜索) trial is fully enrolled and accruing events toward its interim analysis, while the Phase II adjuvant renal cell carcinoma (搜索) trial is also fully enrolled. The program has expanded into the metastatic setting with Phase II studies in first-line metastatic melanoma and squamous non-small cell lung cancer (搜索).
For the cancer antigen therapy program mRNA-4359, the company is enrolling Phase II studies in first-line metastatic melanoma (搜索) and non-small cell lung cancer (搜索) based on encouraging Phase Ib data. Additionally, Moderna dosed the first patient in its T-cell engager program mRNA-2808 (搜索) Phase I trial during the quarter.
Respiratory Vaccine Portfolio Advances
The respiratory vaccine portfolio showed continued momentum with mRESVIA, Moderna's RSV (搜索) vaccine, now approved for adults aged 60 and older in 40 countries and for high-risk adults aged 18-59 in 31 countries. The company expects to complete regulatory submissions for its flu vaccine candidate mRNA-1010 in the United States, Canada, Australia, and Europe by January 2026.
The combination flu-COVID vaccine mRNA-1083 remains under review with the European Medicines Agency, with refiling expected in Canada by the end of 2025. In the US, the company awaits further FDA guidance on refiling plans.
Rare Disease Programs Reach Key Milestones
In rare diseases, Moderna announced reaching target enrollment for the registrational study of its propionic acidemia (搜索) (PA) program. The company presented data from ongoing Phase I/II studies at the International Congress of Inborn Errors of Metabolism. For methylmalonic acidemia (搜索) (MMA), interim Phase I/II data was presented, with the registrational trial expected to start in 2026.
Setback in CMV Development
The company faced a significant setback when its CMV (搜索) vaccine mRNA-1647 failed to meet the primary endpoint for prevention of infection in the Phase III efficacy study. CEO Stéphane Bancel announced: "We will discontinue the development of our CMV vaccine in this indication."
However, Moderna will continue evaluating mRNA-1647 in an ongoing Phase II trial for patients undergoing bone marrow transplantation, where the vaccine may help control CMV (搜索) reactivation rather than prevent initial infection.
Global Manufacturing Expansion
Moderna expanded its global manufacturing footprint with new facilities becoming operational. The company began executing its strategic partnership with Canada through in-country manufacturing, with similar partnerships expected to launch in Australia in Q4 2025 and the UK in Q1 2026. These strategic partnerships are expected to contribute to revenue growth in 2026.
Financial Outlook and Strategic Direction
Looking ahead, Bancel emphasized the company's transformation: "We know that a higher cash balance to exit 2025 and a much lower cost structure when we enter 2025 is the right strategy as we transition from a single pandemic product company to a large diversified portfolio of commercial products in seasonal vaccines, oncology medicines and rare disease medicines."
The company maintains its target of achieving cash breakeven by 2028, supported by continued cost reductions and revenue growth from its diversified portfolio. Moderna plans to provide updated 2026 and 2027 financial targets at its upcoming Analyst Day on November 20, 2025.